{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:53:09Z","timestamp":1781574789926,"version":"3.54.5"},"reference-count":33,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      SURMOUNT\u2010REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard\u2010of\u2010care (SoC) in adults with Class I obesity (BMI \u2265\u200930 and \u2264\u200934.9\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and without diabetes in a UK primary care setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A 5\u2010year, phase 4, multicenter, open\u2010label, pragmatic randomized clinical trial is enabled through access to participants' integrated electronic healthcare record data. The study will enroll approximately 3000 participants from Greater Manchester, UK,\u00a0who are randomly assigned in a 1:1 ratio to receive either tirzepatide and\n                      <jats:styled-content style=\"fixed-case\">SoC<\/jats:styled-content>\n                      or SoC alone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary endpoint is the percent change in body weight from baseline to Month 24, with the time to onset of type 2 diabetes to Month 60 being the key secondary endpoint. Additional endpoints include the impact of tirzepatide versus SoC on obesity\u2010related complications, health\u2010related quality of life, healthcare resource utilization, productivity, employment, and sickness\u2010related absences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SURMOUNT\u2010REAL UK employs a novel study design to evaluate real\u2010world health outcomes and potential long\u2010term benefits for both participants and the healthcare system associated with the delivery of pharmacological obesity treatment at a population level. The study is intended to generate critical evidence to support informed decision\u2010making in obesity management, clinical guideline development, and healthcare policy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier: NCT07247084\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/oby.70247","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:10:07Z","timestamp":1781572207000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>SURMOUNT<\/scp>\n                    \u2010\n                    <scp>REAL UK<\/scp>\n                    : A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity"],"prefix":"10.1002","author":[{"given":"Martin K.","family":"Rutter","sequence":"first","affiliation":[{"name":"Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health University of Manchester  Manchester UK"},{"name":"Diabetes, Endocrinology and Metabolism Centre Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Mount","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Basingstoke UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Martin","family":"Gibson","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health University of Manchester  Manchester UK"},{"name":"NorthWest EHealth (NWEH) Ltd.  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Webb","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Basingstoke UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Marler","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Reed","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Basingstoke UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugdha","family":"Gore","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Ye","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gomez Valderas","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wilding","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health University of Glasgow  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre University of Leicester  Leicester UK"},{"name":"NIHR Leicester Biomedical Research Centre  Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre University of Leicester  Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Batterham","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Basingstoke UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12551"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(24)00316\u20104"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003095\u20103"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15836"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010023\u201033389\u20104"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15785"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679\u2010024\u201000572\u20101"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574\u2010019\u20100176\u20108"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889\u2010021\u201012009\u20108"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679\u2010017\u20100262\u2010y"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23086"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2017\u201000111"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.045"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574\u2010024\u201000979\u20109"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24288"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010024\u201001650\u2010z"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010025\u201003333\u20101"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13752"},{"key":"e_1_2_9_20_1","unstructured":"National Institute for Health and Care Excellence \u201cTirzepatide for Managing Overweight and Obesity \u201daccessed October 22 2025 https:\/\/www.nice.org.uk\/guidance\/ta1026."},{"key":"e_1_2_9_21_1","unstructured":"European Medicines Agency \u201cMounjaro \u201daccessed December 29 2025 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mounjaro."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)01200\u2010X"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16046"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010025\u201001723\u2010w"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410819"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745\u20106215\u201012\u2010S1\u2010A113"},{"key":"e_1_2_9_28_1","volume-title":"WHO STEPS Surveillance Manual: The WHO Stepwise Approach to Chronic Disease Risk Factor Surveillance","author":"World Health Organization","year":"2017"},{"issue":"4","key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1080\/10543406.2011.551334","article-title":"A Mixture Gatekeeping Procedure Based on the Hommel Test for Clinical Trial Applications","volume":"21","author":"Brechenmacher T.","year":"2011","journal-title":"Journal of Biopharmaceutical Statistics"},{"key":"e_1_2_9_30_1","unstructured":"Health Innovation Manchester and Lilly UK \u201cUnderstanding Obesity Care Pathways in Greater Manchester Integrated Care System \u201daccessed December 29 2025 https:\/\/healthinnovationmanchester.com\/wp\u2010content\/uploads\/2025\/11\/UK_Obesity_ManchesterUnderstandingLandscapeFinalReport_Jan24_PP\u2010MG\u2010GB\u20100466.pdf."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl\u20102014\u2010205259"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.18203\/2349\u20103259.ijct20231106"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u2010S008"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/occmed\/kqaf097"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70247","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/oby.70247","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:10:12Z","timestamp":1781572212000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/oby.70247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":33,"alternative-id":["10.1002\/oby.70247"],"URL":"https:\/\/doi.org\/10.1002\/oby.70247","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"2026-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"oby.70247"}}